In a citizen petition posted by the FDA this week, Novo urged the regulator to restrict the ability of compounding pharmacies ...

A range of GLP-1 weight loss drugs are currently on the market. What are they, what do they do, and where are they available?

"Coverage for these weight-loss drugs has significant cost implications for employers, as a previous KFF analysis estimated ...

Novo Nordisk has filed another Citizen's Petition with the FDA seeking to block compounding pharmacies in the US from making ...

The phase 2 ELAD study of Novo Nordisk's once-daily injectable GLP-1 agonist liraglutide in people ... Liraglutide is on the market as Victoza for diabetes and Saxenda for obesity.

The FDA has approved Liraglutide Injection, the first generic version of Victoza, for the treatment of type 2 diabetes.

In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, ...

Novo Nordisk (NOVO) is petitioning the FDA to exclude its diabetes drug liraglutide, also known as Victoza, from a list of ...

Novo Nordisk (NVO) markets liraglutide under the brand names Victoza, Saxenda and Xultophy ... from producing versions of its blockbuster GLP-1 drug semaglutide, which is marketed for weight ...

The US FDA approved the first generic referencing Victoza, a GLP-1 receptor agonist indicated to improve glycemic control.